An investor who bought the rights to a life-saving drug and then hiked the price by more than 5000% says he'll now lower the figure, after a massive backlash.

Martin Shkreli's Turing Pharmaceuticals began charging around €750 euro for Daraprim last month.

The drug treats toxoplasmosis, which can cause complications for AIDS patients.

Mr Schkreli insists he wasn't being greedy:

Previously, he discussed why he placed the price on this particular drug: